Katiuscia Bonezzi
Mario Negri Institute for Pharmacological Research
11 Papers
152 Citations
Katiuscia Bonezzi is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Angiogenesis & Mesenchymal stem cell. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.
Katiuscia Bonezzi,Giulia Taraboletti,Patrizia Borsotti,Fabio Bellina,Renzo Rossi,Raffaella Giavazzi +5 more
TL;DR: Highly cytotoxic 1,5-diaryl-1H-imidazoles were studied and substitution patterns on the imidazole ring, responsible for greater interaction energy with tubulin and higher cytotoxicity, were not associated to greater vascular disrupting activity.
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain
Barbara Margosio,Marco Rusnati,Katiuscia Bonezzi,Blue leaf A Cordes,Douglas S. Annis,Chiara Urbinati,Raffaella Giavazzi,Marco Presta,Domenico Ribatti,Deane F. Mosher,Giulia Taraboletti +10 more
TL;DR: The finding that this domain is active in inhibiting angiogenesis indicates that the type III repeats represent a novel antiangiogenic domain of thrombospondin-1.
64
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
Michele Martinelli,Katiuscia Bonezzi,E Riccardi,E Kuhn,Roberta Frapolli,Massimo Zucchetti,Anderson J. Ryan,Giulia Taraboletti,Raffaella Giavazzi +8 more
TL;DR: Findings show that schedule, sequence and timing are crucial in determining the antitumour efficacy of PTX in combination with ZD6126 and could be exploited as readouts to optimise schedules and maximise therapeutic efficacy.
Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells
Cristina Belgiovine,Roberta Frapolli,Katiuscia Bonezzi,Ilaria Chiodi,Francesco Favero,Maurizia Mello-Grand,Angelo Paolo Dei Tos,Elena Giulotto,Giulia Taraboletti,Maurizio D'Incalci,Chiara Mondello +10 more
TL;DR: Results indicate that, during neoplastic transformation, cells of mesenchymal origin can switch from a mesenchyal mode of movement to an amoeboid one, and point to Rnd3 as a possible regulator of meschymal tumor cell invasion and to ROCK as a potential therapeutic target for sarcomas.
Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies
Katiuscia Bonezzi,Dorina Belotti,Brian J. North,Carmen Ghilardi,Patrizia Borsotti,Andrea Resovi,Paolo Ubezio,Antonella Riva,Raffaella Giavazzi,Eric Verdin,Giulia Taraboletti +10 more
TL;DR: A role for SIRT2 in the regulation of cell motility is indicated and suggests that therapies combining sirtuin inhibitors and taxanes could be used to treatcell motility-based pathologic processes such as tumor angiogenesis, invasion, and metastasis.
31